IDH2 and glioma: Although IDH mutant gliomas with TP53 mutations and IDH wild-type gliomas were both associated with high recurrence rates, the median PFS in the latter group was significantly shorter than that in the former group (Table 1B and Fig 1C; hazard ratio = 0.229; 95% confidence interval [CI]: 0.142–0.368; p < 0.0001).